FDA Finalizes Guidance Documents Aimed At Easing Post-Pandemic Regulatory Transitions
Executive Summary
The documents describe the US agency’s preferred approach toward products cleared under EUAs or other alternate approaches during the COVID-19 public health emergency.
You may also be interested in...
‘Banner Year’ For FDA’s Device Center Includes Record Number Of Novel Authorizations
A new annual report argues that last year was both transformative and historic for the US FDA’s Center for Devices and Radiological Health. The center authorized the highest number of novel medical devices in history while turning the corner on the pandemic.
Regulatory And Commercial Should Be 'Hand In Hand' For Dx Success, Expert Says
Considering where and how a test will be used, and what kind of evidence regulators will want before clearing it, is key for developers of at home and point-of-care diagnostics.
Shuren: ‘You Can’t Be Expecting Us To Just Sit Back’
In a wide-ranging speech at FDLI’s 2023 annual meeting, CDRH director Jeffrey Shuren pledged to move forward with regulatory action on lab-developed tests and sketched plans for improved regulation of medical apps.